HD-OPM Archive
Topics › Cancer

SGLT2 inhibitors linked to delayed progression in prostate cancer on hormone therapy

Louis Nervegna · Jan 19, 2026 · ♥ 6 reactions · 4 comments · original Facebook post
CancerInsulin resistance & diabetes
AI summary & key facts

Louis shares a JAMA Oncology finding that men with prostate cancer on hormone therapy using SGLT2 inhibitors had lower risk of treatment failure and delayed progression.

This class of diabetes drugs help your kidneys excrete up to 100 grams of sugar per day. They may be helpful in treating cancer, particularly prostate cancer.

#sglt2HD #cancerHD #prostatecancerHD #diabetesHD

Research cited

Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit.

Paper · JAMA Oncol · 2026Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone TherapyImportance While preliminary evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors for diabetes may have antitumorigenic effects, their potential benefits in prostate cancer remain unexplored. Understanding their association with outcomes among patients undergoing hormone therapy could inform future adjunct treatment strategies. Objective To evaluate whether the use of SGLT2 inhibitors is…jamanetwork.comPlots show cumulative incidence differences. A) Time to ADT failure: 5-year -10.0%, 10-year -11.1%. B) Time to NHA failure: 5-year -13.4%, 10-year -8.4%. C) Disease-specific survival: 5-year -3.1%, 10-year -3.7%. D) Overall survival: 5-year -7.5%, 10-year -8.5%.
← newer: Harvard begins clinical trials of low-dose lithium for Alzheolder: Full-fat yogurt lowered ApoB 4 mg/dL while butter raised it →